First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue(Tohoku University Hospital), Koichi Hagiwara(Jichi Medical University), Hitoshi Miyazawa(Saitama Medical University), Akihiko Gemma(Nippon Medical School), Shoji Okinaga(Tohoku University), Kenji Ikebuchi(Hokkaido University Hospital), Yasuo Saijo(Niigata University), Kazuhiro Usui(Hokkaido University Hospital), Masahiro Ando, Iwao Mikami(Hokkaido University Hospital), Satoshi Morita(Kyoto University), Kunihiko Kobayashi(Hokkaido University Hospital), Toshihiro Nukiwa(Tohoku University), Tomoaki Tanaka(Saitama Medical University), Koichi Yamazaki(Hokkaido University Hospital), Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 516
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
|Science Translational Medicine|2011|530